Novavax Plunges After Respiratory Disease Vaccine Fails in Study

Novavax Inc. shares plunged after the company said its vaccine for a potentially lethal respiratory virus failed to meet its main goals in a final-stage study in elderly patients, hurting prospects for the company’s most anticipated medicine.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.